[Myasthenia gravis].
This article reviews the basic and advanced treatment options of the different disease subtypes including plasma exchange and immunoglobulins for treatment in a myasthenic crisis. Recently, clinical approval of eculizumab, a complement inhibitor, enriched the pharmacological armamentarium for AChR antibody-positive MG patients not appropriately responding to immunosuppression alone.
PMID: 31538208 [PubMed - as supplied by publisher]
Source: Der Nervenarzt - Category: Neurology Authors: Müllges W, Stoll G Tags: Nervenarzt Source Type: research
More News: Autoimmune Disease | Brain | Myasthenia Gravis | Neurology | Paraneoplastic Syndrome | Sports Medicine